Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole) and spiramycin in pregnant mice infected with Toxoplasma gondii (Beverley strain).
The effects of cotrimoxazole (CTX) and spiramycin (Spir) in mice infected in midpregnancy with the Beverley (Bev) strain of Toxoplasma gondii were compared. Therapeutic effectiveness was determined according to the following parameters: rate of successful delivery, litter size, offspring weight and survival. When compared with the uninfected untreated control group, CTX showed a more beneficial therapeutic effect than Spir, with a statistically significant increase in the rate of both successful delivery and offspring survival. Results based on antitoxoplasma antibody determinations in the offspring indicated a better in utero control of congenital infection by CTX than by Spir.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D001724:Birth Weight / Q000187:drug effects; D000013:Congenital Abnormalities / Q000209:etiology; D036861:Delivery, Obstetric; D004338:Drug Combinations / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005260:Female; D007933:Leucomycins / Q000627:therapeutic use*; D008098:Litter Size / Q000187:drug effects; D051379:Mice; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014122:Toxoplasma / Q000276:immunology; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000906:Antibodies; D004338:Drug Combinations; D007933:Leucomycins; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole